22UA:ETR
BioNTech SE - ADR
€ 79.80
arrow_downward
-1.60%(-1.30) 1D
10-р сарын 14, 17:35:45 (GMT+2) · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 22UA...
Open
€ 80.25
High
€ 81.25
Low
€ 79.70
Mkt. cap
22.27 тэрбум
Avg. vol.
24.78 мян
Volume
25.88 мян
52-wk high
€ 105.70
52-wk low
€ 68.30
No. of employees
8 мян
Open
€ 80.25
High
€ 81.25
Low
€ 79.70
Mkt. cap
22.27 тэрбум
Avg. vol.
24.78 мян
Volume
25.88 мян
52-wk high
€ 105.70
52-wk low
€ 68.30
No. of employees
8 мян
News stories
From web sources and news partners
Pluang
·
6 цагийн өмнө
BioNTech shares drop 7.13% after trial failure raises concerns over oncology program claims
Simply Wall Street
·
20 цагийн өмнө
BioNTech Stock Faces Questions After Cancer Trial Missed Progression Free Survival Goal
TradingKey
·
1 өдрийн өмнө
Biontech SE Stock (BNTX) Closed Down by 7.13% on Oct 13: Drivers Behind the Movement
GuruFocus
·
1 өдрийн өмнө
BioNTech (BNTX) Shares Slide After BNT113 Vaccine Misses Progres
Profile
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
About BioNTech SE - ADR